Arocaine-A DC Injection

Local anesthesia in Dental Procedures

Local, Infiltrative, or Conductive Anesthesia in Dental Procedures Infiltration: 0.5-2.5 mL injection of 4% solution; 20-100 mg total dose Nerve block: 0.5-3.4 mL injection of 4% solution; 20-136 mg total dose Oral surgery: 1-5.1 mL injection of 4% solution; 40-204 mg total dose Not to exceed 7 mg/kg (0.175 mL/kg)

Local, Infiltrative, or Conductive Anesthesia in Dental Procedures <4 years old: Safey and efficacy not established 4-16 years old: Use lower end of dose range No more than 7 mg/kg (0.175 mL/kg)

No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Tachycardia, hypertension, cerebral arteriosclerosis, ischaemic heart disease, IV admin, anaesthetise digits or appendages, myasthenia gravis.

Accidental Intravascular Injection: May be associated with convulsions followed by coma and respiratory arrest. Resuscitative equipment, oxygen and other resuscitative drugs should be available. Systemic Toxicity: Systemic absorption of Articaine + Epinephrine can produce effects on the central nervous and cardiovascular systems. Vasoconstrictor Toxicity: Local anesthetic solutions like Articaine + Epinephrine that contain a vasoconstrictor should be used cautiously, especially in patients with impaired cardiovascular function or vascular disease. Methemoglobinemia: Cases of methemoglobinemia have been reported in association with local anesthetic use.

C Pregnancy Category: C Lactation: excretion in milk unknown; use with caution

Monoamine Oxidase Inhibitors, Nonselective Beta-Adrenergic Antagonists, or Tricyclic Antidepressants: May produce severe, prolonged hypertension. Phenothiazines and Butyrophenones: May reduce or reverse the pressor effect of epinephrine. Concurrent use of these agents should be avoided; however, in situations when concurrent therapy is necessary, careful patient monitoring is essential. Contraindicated (15) disopyramide ibutilide indapamide iobenguane I 123 isocarboxazid linezolid lurasidone pentamidine phenelzine pimozide procainamide quinidine selegiline transdermal sotalol tranylcypromine

1-10% Facial edema,Headache,Pain,Paresthesia,Sleepiness,Gingivitis,Nausea,Vomiting,Infection Frequency Not Defined Systemic absorption of significant concentrations of local anesthetic can produce myocardial depression, cardiac conduction changes, CNS excitation, convulsions, and cardiorespiratory arrest Potentially Fatal: CNS toxicity (due to inadvertent IV admin), medullary depression with tonic & clonic convulsions; ventricular fibrillation; severe hypertension with cerebral haemorrhage and pulmonary oedema; unconsciousness; possibly respiratory arrest. Allergic reactions including anaphylactic symptoms and possibly life threatening asthmatic episodes in susceptible patients may occur due to sodium metabisulphate constituent. Central nerve blocks may cause CV depression (especially in hypovolaemia). Retrobulbar inj may reach subarachnoid space causing CV collapse, apnoea, convulsions, temporary blindness. Paracervical block may cause foetal bradycardia/tachycardia (careful monitoring of foetal heart rate is necessary).

Local anesthetics prevent generation/conduction of nerve impulses by reducing sodium permeability and increasing action potential threshold.

Arocaine-A DC 4 gm + 1 mg/100 ml Injection manufactured by Jayson Pharmaceuticals Ltd.. Its generic name is Articaine Hydrochloride + Epinephrine.